XML 42 R24.htm IDEA: XBRL DOCUMENT
v3.24.0.1

PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES | 12 Months Ended
--- | ---
Dec. 31, 2023
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES |
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES | PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES In January 2016, the Company acquired the right, title and interest in the NDAs for Cortrophin Gel and Cortrophin-Zinc. Subsequently, the Company assembled a Cortrophin Gel re-commercialization team of scientists, executed a long-term supply agreement with a supplier of pig pituitary glands, our primary raw material for corticotrophin API, executed a long-term supply agreement with an API manufacturer, with whom ANI has advanced the manufacture of corticotropin API via manufacture of commercial-scale batches, and executed a long-term commercial supply agreement with a current good manufacturing practice (“cGMP”) aseptic fill contract manufacturer. Prior to the third quarter 2019, all purchases of material, including pig pituitary glands and API, related to the re-commercialization efforts were consumed in research and development activities and recognized as research and development expense in the period in which they were incurred. In the third quarter of 2019, the purchase of materials commenced that were intended to be used commercially in anticipation of FDA approval of Cortrophin Gel and the resultant product launch. The FDA granted approval of the sNDA of this product on October 29, 2021. Prior to FDA approval, under U.S. GAAP, the Company was prohibited from capitalizing these pre-launch purchases of materials as inventory, and accordingly, they were charged to expense in the period in which they were incurred. Subsequent to approval, these purchases are recorded as inventory at net realizable value. During the year ended December 31, 2021, the Company recognized $0.8 million of charges for the purchase of materials. Other charges were incurred directly related to the Cortrophin pre-launch commercialization efforts, including, but not limited to, sales and marketing and consulting expenses. During the year ended December 31, 2021, the Company incurred $14.0 million of these charges, which are included on the consolidated statements of operations as a selling, general, and administrative expense. There were no comparable expenses in 2023 and 2022.

X
- References No definition available. + Details
Name: | anip_CortrophinPreLaunchChargesAbstract
Namespace Prefix: | anip_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for cortrophin pre-launch charges. + References No definition available. + Details
Name: | anip_CortrophinPreLaunchChargesTextBlock
Namespace Prefix: | anip_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration